PositiveID Corporation to add complementary non-invasive glucose-level testing technologies to Healthid division

PositiveID Corporation ("PositiveID" or the “Company”) (NASDAQ: PSID) announced today that it plans to expand its HealthID division by adding products and tools for the daily management of diabetes. In addition to the continued development of its in vivo glucose-sensing RFID microchip to detect glucose levels in the human body, the Company is planning to broaden its technology platform by adding complementary non-invasive glucose-level testing technologies.

According to a November 2009 study by researchers at the University of Chicago published in the journal Diabetes Care, the number of diabetics in the U.S., which currently stands at 23.7 million, may almost double in 25 years, and the annual cost of treating them may triple to $336 billion.

The Company, in conjunction with development partner RECEPTORS LLC (“Receptors”), a technology company whose AFFINITY by DESIGN™ chemistry platform can be applied to the development of selective binding products, is in Phase II development of an in vivo glucose-sensing RFID microchip to detect glucose levels in the human body. The goal of Phase II is to develop a proof-of-principal sensing system consisting of a Combinatorial Artificial Receptors Array (CARA™) modified support and its complementary fluorophore labeled synthetic competitor agent. The companies expect that this sensing system will demonstrate a glucose concentration response in model blood and interstitial fluid matrices. Phase II is expected to be completed in the second quarter of 2010 and will build on Phase I, which successfully demonstrated the bench-top format application of the glucose-sensing system to the detection of glucose levels.

In addition to its current diabetes development project, PositiveID is actively looking to acquire, license or develop other complementary non-invasive glucose level testing products to help enhance daily diabetes management techniques. Proper diabetic care can help prevent or minimize a variety of health conditions, including blindness, kidney failure, loss of limbs, heart attack and stroke.

Scott R. Silverman, Chairman and CEO of PositiveID, stated, “There are a variety of important research projects underway in the scientific community to better manage the growing epidemic of diabetes while improving the quality of diabetics’ daily care. Diabetics should not have to prick their fingers multiple times each day. We believe alternative, non-invasive technologies should (and will) be the way of the future. We also believe that with our current development of an implantable glucose sensing RFID microchip, PositiveID can become a leader in this growing and needed market by expanding our pipeline of potential non-invasive diabetic care and treatment products.”